Rat Insulin-like Growth Factors 1 （IGF-1）ELISA Kit

（96T）

?          This immunoassay kit allows for the in vitro quantitative determination of rat IGF-1 concentrations in serum, plasma, Cell Culture Supernates and Tissue Homogenates.

?          Expiration date six months from the date of manufacture

 

廈門慧嘉生物經(jīng)營(yíng)ELISA試劑盒及抗體、細(xì)胞因子、生化試劑、耗材等生物試劑產(chǎn)品。誠信經(jīng)營(yíng)，價(jià)格實(shí)惠，服務(wù)周到，質(zhì)量有保證。歡迎廣告老師來詢！:  : http://www.biohj.com/download.aspx（說明書下載）

 

Insulin-like Growth Factor I （IGF-I）, also known as somatomedin C, is a member of the insulin superfamily. It was originally discovered as a mediator of growth hormone actions on somatic cell growth, but has also been shown to be an important regulator of cell metabolism, differentiation and survival. IGF-I is synthesized as a preproprotein that is proteolytically cleaved to generate the mature protein linked by three disulfide bonds. Mature IGF-I is highly conserved among mammals, with 100% sequence identity between the Porcine, bovine, porcine, equine and canine proteins. IGF-I is synthesized in the liver and multiple other tissues. It is found in blood and other body fluids as a complex with specific high affinity IGF binding proteins （IGFBP-1to-6）. The IGFBPs are expressed in specific patterns during development. They are modulators of IGF actions, which control IGF bioavailability to specific cell-surface receptors. Their functions are further regulated by IGFBP proteases, which proteolytically cleave the IGFBPs to lower the affinity with which they bind IGFs and increase IGF bioavailability. Some IGFBPs also have IGF-independent effects on cell functions. IGF-I circulates primarily as a ternary complex with IGFBP-3 or IGFBP-5 and the acid-labile subunit （ALS）. Some IGF-I is also present in binary complexes with other IGFBPs. Whereas the ternary complexes are generally restricted to the vasculature, the binary complexes freely enter the tissues.

IGF-I actions are mediated by two type I transmembrane receptor tyrosine kinases: the IGF-I receptor （IGF-I R）, and the insulin receptor （INS R） that exists in two alternatively spliced isoforms （INS R-A and -B）. Both IGF-I R and INS R share a highly homologous structure and are ubiquitously expressed. Functional IGF-I receptors are tetrameric glycoproteins composed of two disulfide-linked IGF-I Rs or disulfide-linked hybrids of one IGF-I R and one INS R. Whereas IGF-I binds with high-affinity to homodimeric IGF-I R and heterdimeric IGF-I R:INS R-A or –B hybrids, high-affinity binding of insulin is observed only with dimeric INS R or IGF-I R:INS R-A hybrid but not with IGF-I R:INS R-B hybrid. The signaling responses from the various receptors are different depending whether insulin or IGF-I is used as the activating ligand.

The microtiter plate provided in this kit has been pre-coated with an antibody specific to IGF-1. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for IGF-1. and Avidin conjugated to Horseradish Peroxidase （HRP） is added to each microplate well and incubated. Then a TMB （3,3'5, 5' tetramethyl-benzidine） substrate solution is added to each well. Only those wells that contain IGF-1., biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of IGF-1. in the samples is then determined by comparing the

O.D. of the samples to the standard curve.

0.16 ng/ml-10 ng/ml. The standard curve concentrations used for the ELISA’s were 10 ng/ml,5 ng/ml, 2.5 ng/ml, 1.25 ng/ml, 0.62 ng/ml, 0.32 ng/ml, 0.16 ng/ml.

This assay recognizes rat IGF-1 No significant cross-reactivity or interference was observed.

The minimum detectable dose of rat IGF-1 is typically less than 0.04 ng/ml. The sensitivity of this assay, or Lower Limit of Detection （LLD） was defined as the lowest protein concentration that could be differentiated from zero.

Assay plate 1 Standard 2 Sample Diluent 2 x 20 ml Biotin-antibody Diluent 1 x 10 ml HRP-avidin Diluent 1 x 10 ml Biotin-antibody 1 x 120μl HRP-avidin 1 x 120μl

1 x 20 ml

Wash Buffer

（25×concentrate）

TMB Substrate 1 x 10 ml

Stop Solution 1 x 10 ml

1          Unopened test kits should be stored at 2-8?C upon receipt and the microtiter plate should be kept in a sealed bag. The test kit may be used throughout the expiration date of the kit, provided it is stored as prescribed above. Refer to the package label for the expiration date.

2          Opened test plate should be stored at 2-8?C in the aluminum foil bag with desiccants to minimize exposure to damp air. The kits will remain stable until the expiring date shown, provided it is stored as prescribed above.

3          A microtiter plate reader with a bandwidth of 10 nm or less and an optical density range of 0-3 OD or greater at 450nm wavelength is acceptable for use in absorbance measurement.

 

1          Wash Buffer If crystals have formed in the concentrate, warm up to room temperature and mix gently until the crystals have compley dissolved. Dilute 20 ml of Wash Buffer Concentrate into deionized or distilled water to prepare 500 ml of Wash Buffer.

2          Standard Centrifuge the standard vial at 6000-10000rpm for 30s. Reconstitute the Standard with 1.0 ml of Sample Diluent. This reconstitution produces a stock solution of 10 ng/ml. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making serial dilutions. The undiluted standard serves as the high standard （10 ng/ml）. The Sample Diluent serves as the zero standard （0 ng/ml）. Prepare fresh for each assay. Use within 4 hours and discard after use.

3          Biotin-antibody Centrifuge the vial before opening. Dilute to the working concentration using Biotin-antibody Diluent（1:100）, respectively.

4          HRP-avidin Centrifuge the vial before opening. Dilute to the working concentration using HRP-avidin Diluent（1:100）, respectively.

 

?          Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.

?          Pipettes and pipette tips.

?          Deionized or distilled water.

?          Squirt bottle, manifold dispenser, or automated microplate washer.

?          An incubator which can provide stable incubation conditions up to 37°C±0.5°C.

 

?          Serum Use a serum separator tube （SST） and allow samples to clot for 30 minutes before centrifugation for 15 minutes at 1000 g. Remove serum and assay immediay or aliquot and store samples at -20°C. Centrifuge the sample again after thawing before the assay. Avoid repeated freeze-thaw cycles.

?          Plasma Collect plasma using citrate, EDTA, or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 g within 30 minutes of collection. Assay immediay or aliquot and store samples at -20°C. Centrifuge the sample again after thawing before the assay. Avoid repeated freeze-thaw cycles.

?          Cell Culture Supernates Remove particulates by centrifugation and assay immediay or aliquot and store samples at -20° C. Avoid repeated freeze-thaw cycles.

?          Tissue Homogenates 100mg tissue was rinsed with 1X PBS, homogenized in 1 mL of 1X PBS and stored overnight at -20°C. After two freeze-thaw cycles were performed to break the cell membranes, the homogenates were centrifuged for 5 minutes at 5000 x g. The supernate was assayed and removed immediay. Alternatively, aliquot and store samples at -20°C. Centrifuge the sample again after thawing before the assay. Avoid repeated freeze-thaw cycles.

 

1          Recommend to dilute the serum or plasma samples with Sample Diluent（1:200） before test. The suggested 200-fold dilution can be achieved by adding 5μl sample to 95μl of Sample Diluent. Complete the 200-fold dilution by adding 25μl of this solution to 225μl of Sample Diluent. The recommended dilution factor is for reference only. The optimal dilution factor should be determined by users according to their particular experiments.

2          Add 100μl of Standard, Blank, or Sample per well. Cover with the adhesive strip. Incubate for 2 hours at 37°C.

3          Remove the liquid of each well, don’t wash.

4          Add 100μl of Biotin-antibody working solution to each well. Incubate for 1 hour at 37°C. Biotin-antibody working solution may appear cloudy. Warm up to room temperature and mix gently until solution appears uniform.

5          Aspirate each well and wash, repeating the process three times for a

 

total of three washes. Wash: Fill each well with Wash Buffer （200μl） and

let it stand for 2 minutes, then remove the liquid by flicking the plate over a sink. The remaining drops are removed by patting the plate on a paper towel. Complete removal of liquid at each step is essential to good performance.

1          Add 100μl of HRP-avidin working solution to each well. Cover the microtiter plate with a new adhesive strip. Incubate for 1 hour at 37°C.

2          Repeat the aspiration and wash five times as step 5.

3          Add 90μl of TMB Substrate to each well. Incubate for 10-30 minutes at 37°C. Keeping the plate away from drafts and other temperature fluctuations in the dark.

4          Add 50μl of Stop Solution to each well when the first four wells containing the highest concentration of standards develop obvious blue color. If color change does not appear uniform, gently tap the plate to ensure thorough mixing.

5          Determine the optical density of each well within 30 minutes, using a microplate reader set to 450 nm.

 

Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density. Create a standard curve by reducing the data using computer software capable of generating a four parameter logistic （4-PL） curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the x-axis against the concentration on the y-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the IGF-1 concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

?          The kit should not be used beyond the expiration date on the kit label.

?          Do not mix or substitute reagents with those from other lots or sources.

?          It is important that the Standard Diluent selected for the standard curve be consistent with the samples being assayed.

?          If samples generate values higher than the highest standard, dilute the samples with the appropriate Standard Diluent and repeat the assay.

?          Any variation in Standard Diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.

?          This assay is designed to eliminate interference by soluble receptors, binding proteins, and other factors present in biological samples. Until all factors have been tested in the Immunoassay, the possibility of interference cannot be excluded.

 

?          Centrifuge vials before opening to collect contents.

?          When mixing or reconstituting protein solutions, always avoid foaming.

?          To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.

?          When using an automated plate washer, adding a 30 second soak period following the addition of wash buffer, and/or rotating the plate 180 degrees between wash steps may improve assay precision.

?          To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.

?          Substrate Solution should remain colorless or light blue until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless or light blue to gradations of blue.

?          Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.